Notícias e Atividades da Upstream Bio

Upstream Bio é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Upstream Bio é uma empresa listada sob o símbolo UPB (US).

Veja o organograma con seus 28 executivos principais

Biografias mais buscadas da Upstream Bio

• Rand Sutherland, Chief Executive Officer and Director
• Marcella Ruddy, Director
• Daniella Beckman, Director

Recentes movimentos de executivos em Upstream Bio

• Bryan Johnson, ingressou na Companhia como Senior Director, Analytical  (Notícia publicada em 4 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Upstream Bio.

Upstream Bio possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Upstream Bio

• Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 — Sun, 06/14/2026 - 10:00
• Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 — Mon, 06/08/2026 - 07:00
• Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference — Wed, 06/03/2026 - 07:00
• Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference — Mon, 05/18/2026 - 11:30
• Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights — Wed, 05/13/2026 - 07:01
• Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference — Fri, 04/17/2026 - 07:00
• Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results — Thu, 03/26/2026 - 07:00
• Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting — Sun, 03/01/2026 - 09:45
• Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 — Thu, 02/26/2026 - 07:00
• Upstream Bio to Participate in Upcoming March Investor Conferences — Wed, 02/25/2026 - 07:00
• View more press releases Close

Redes sociais sobre Upstream Bio

• Upstream Bio na Wikipedia, Google News e Yahoo Finance
• Upstream Bio na LinkedIn, X (Twitter) e YouTube